piracetam has been researched along with Alcohol Abuse in 32 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol." | 9.16 | The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012) |
| "Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol." | 5.16 | The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012) |
| "This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders." | 5.13 | Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. ( Levin, FR; Mariani, JJ, 2008) |
| "The levetiracetam XR treatment group showed significantly fewer consequences than did the placebo group during the maintenance period (p = 0." | 2.77 | A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. ( A Tompkins, D; Brunette, MF; Ciraulo, D; Devine, E; Falk, DE; Fertig, JB; Green, AI; Johnson, B; Kampman, K; Litten, RZ; Mattson, ME; Pettinati, H; Ransom, J; Rickman, WJ; Ryan, ML; Scott, C; Stout, R; Strain, EC; Tiouririne, NA, 2012) |
| "Diazepam was added when symptom triggered as rescue medication." | 2.75 | Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. ( Heinz, A; Hinzpeter, A; Kienast, T; Plenge, T; Preuss, UW; Richter, C; Schaefer, M; Schmidt, F, 2010) |
| "Levetiracetam was well tolerated by most subjects." | 2.73 | The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. ( Afshar, M; Ciraulo, D; Devine, E; Knapp, C; Koplow, J; Piechniczek-Buczek, J; Richambault, C; Sarid-Segal, O; Sickles, L; Uwodukunda, E, 2008) |
| " After screening eligibility for outpatient detoxification, 9 alcohol-dependent patients received levetiracetam and tiapride in a flexible dosage regimen up to 2500 and 300 mg/d, respectively, for a maximum of 7 days." | 1.37 | A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series. ( Banas, R; Förg, A; Heimann, HM; Hein, J; Heinz, A; Müller, CA; Schäfer, M; Volkmar, K, 2011) |
| "The findings of this study provide some evidence that levetiracetam is an efficacious and safe treatment option for outpatient alcohol detoxification." | 1.36 | Efficacy and safety of levetiracetam for outpatient alcohol detoxification. ( Förg, A; Heimann, HM; Hein, J; Heinz, A; Hinzpeter, A; Müller, CA; Schäfer, M; Schneider, S; Volkmar, K, 2010) |
| "Piracetam was found to markedly decrease the formation of neuronal lipofuscin." | 1.28 | The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: a quantitative study. ( Andrade, JP; Brandão, F; Cadete-Leite, A; Madeira, MD; Paula-Barbosa, MM; Pinho, MC, 1991) |
| "Finally it is suggested that insomnia and the loss of REM sleep may also contribute to the onset of the condition." | 1.27 | [Changes in the circadian rhythm of urinary cyclic adenosine monophosphate during the alcoholic withdrawal syndrome and related neurobiological correlations]. ( Cedaro, P; Di Piazza, V; Geatti, O; Lattuada, L; Marchetti, E; Nardoni, A, 1985) |
| " Long-term administration of piracetam or 3-oxypyridine derivative (300 and 50 mg/kg, respectively, i." | 1.27 | [Neurophysiological analysis of the correction by nootropic substances of disorders in the bioelectric activity of the brain in animals during chronic administration of ethanol]. ( Bogdanov, NN; Krapivin, SV; Voronin, KE, 1988) |
| "The enhanced seizure susceptibility after a single dose of ethanol was abolished by piracetam and MGO." | 1.27 | Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility. ( Andreas, K; Dienel, A; Schmidt, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (46.88) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 10 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Youland, KM | 1 |
| Miller, RF | 1 |
| Mahoney, LJ | 1 |
| Borgert, AJ | 1 |
| Gundrum, JD | 1 |
| Sarid-Segal, O | 1 |
| Piechniczek-Buczek, J | 1 |
| Knapp, C | 1 |
| Afshar, M | 1 |
| Devine, E | 2 |
| Sickles, L | 1 |
| Uwodukunda, E | 1 |
| Richambault, C | 1 |
| Koplow, J | 1 |
| Ciraulo, D | 2 |
| Mariani, JJ | 1 |
| Levin, FR | 1 |
| Müller, CA | 2 |
| Schäfer, M | 2 |
| Schneider, S | 1 |
| Heimann, HM | 2 |
| Hinzpeter, A | 3 |
| Volkmar, K | 3 |
| Förg, A | 3 |
| Heinz, A | 5 |
| Hein, J | 2 |
| Richter, C | 3 |
| Schmidt, F | 1 |
| Kienast, T | 2 |
| Preuss, UW | 2 |
| Plenge, T | 1 |
| Schaefer, M | 3 |
| Zalewska-Kaszubska, J | 1 |
| Bajer, B | 1 |
| Czarnecka, E | 1 |
| Dyr, W | 1 |
| Gorska, D | 1 |
| Banas, R | 1 |
| Fertig, JB | 1 |
| Ryan, ML | 1 |
| Falk, DE | 1 |
| Litten, RZ | 1 |
| Mattson, ME | 1 |
| Ransom, J | 1 |
| Rickman, WJ | 1 |
| Scott, C | 1 |
| Green, AI | 1 |
| Tiouririne, NA | 1 |
| Johnson, B | 1 |
| Pettinati, H | 1 |
| Strain, EC | 1 |
| Brunette, MF | 1 |
| Kampman, K | 1 |
| A Tompkins, D | 1 |
| Stout, R | 1 |
| Mitchell, JM | 1 |
| Grossman, LE | 1 |
| Coker, AR | 1 |
| Messing, RO | 1 |
| Effenberger, S | 1 |
| Bschor, T | 1 |
| Bonnet, U | 1 |
| Haasen, C | 1 |
| Glauner, T | 1 |
| Le Strat, Y | 1 |
| Geisler, F | 1 |
| Smyth, M | 1 |
| Oechtering, J | 1 |
| Tuetuencue, S | 1 |
| Klostermann, F | 1 |
| Nolte, CH | 1 |
| Krebs, M | 1 |
| Leopold, K | 1 |
| Perfilova, VN | 2 |
| Ostrovskii, OV | 1 |
| Verovskii, VE | 1 |
| Popova, TA | 1 |
| Lebedeva, SA | 2 |
| Dib, H | 1 |
| Tiurenkov, IN | 1 |
| Parent, M | 1 |
| Jadot, M | 1 |
| Toussaint, C | 1 |
| Masson, AM | 1 |
| Kaiumov, BP | 1 |
| Sokolova, GB | 1 |
| Ziia, AV | 1 |
| Suvorova, VI | 1 |
| Braude, VI | 1 |
| Glik, MS | 1 |
| Entin, GM | 1 |
| Dencker, SJ | 1 |
| Wilhelmson, G | 1 |
| Carlsson, E | 1 |
| Bereen, FJ | 1 |
| Binder, S | 1 |
| Doddabela, P | 1 |
| Ulbricht, B | 1 |
| Godard, JP | 1 |
| Goerens, C | 1 |
| Grelier, C | 1 |
| Paula-Barbosa, MM | 1 |
| Brandão, F | 1 |
| Pinho, MC | 1 |
| Andrade, JP | 1 |
| Madeira, MD | 1 |
| Cadete-Leite, A | 1 |
| Salimov, RM | 1 |
| Viglinskaia, IV | 1 |
| Sluchevskiĭ, FI | 1 |
| Tikhomirov, SM | 1 |
| Bakharev, VD | 1 |
| Nardoni, A | 1 |
| Di Piazza, V | 1 |
| Marchetti, E | 1 |
| Geatti, O | 1 |
| Cedaro, P | 1 |
| Lattuada, L | 1 |
| Shabanov, PD | 1 |
| Grinenko, AIa | 1 |
| Kalishevich, SIu | 1 |
| Barnas, C | 2 |
| Miller, C | 2 |
| Gunther, V | 2 |
| Fleischhacker, WW | 2 |
| Krapivin, SV | 1 |
| Bogdanov, NN | 1 |
| Voronin, KE | 1 |
| Lieder, F | 1 |
| Dienel, A | 1 |
| Andreas, K | 1 |
| Schmidt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome [Sicherheit Und Wirksamkeit Von Levetiracetam (Keppra) für Die Behandlung Des stationären Alkoholentzugsyndroms][NCT00146471] | Phase 3 | 120 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers[NCT00970814] | Phase 2 | 130 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients[NCT00758277] | Phase 3 | 201 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
based on self report (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | drinks per day (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 6.3 |
| Levetiracetam and BBCET | 7.1 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | percentage of heavy drinking days (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 41.2 |
| Levetiracetam and BBCET | 45.8 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Weeks 5-14
| Intervention | percentage of subjects (Number) |
|---|---|
| Sugar Pill and BBCET | 18.2 |
| Levetiracetam and BBCET | 14.1 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
13 trials available for piracetam and Alcohol Abuse
| Article | Year |
|---|---|
The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.
Topics: Alcoholism; Anticonvulsants; Brain; Female; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Rec | 2008 |
Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Diagnosis, Dual (Psychiatry); Female; Humans | 2008 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial.
Topics: Adult; Alcoholism; Anticonvulsants; Diazepam; Double-Blind Method; Female; Humans; Levetiracetam; Ma | 2010 |
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
Topics: Adult; Affect; Aged; Alcoholism; Anticonvulsants; Anxiety; Breath Tests; Delayed-Action Preparations | 2012 |
The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers.
Topics: Alcohol Drinking; Alcoholism; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; | 2012 |
Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Behavior, Addictive; Female; Humans; Levetirac | 2012 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Piracetam and chlormethiazole in acute alcohol withdrawal: a controlled clinical trial.
Topics: Adult; Alcoholism; Chlormethiazole; Clinical Trials as Topic; Humans; Libido; Male; Middle Aged; Pir | 1978 |
[The efficacy of Piracetam on the mental functional capacity of chronic alcoholics (author's transl)].
Topics: Alcoholism; Behavior; Brain Damage, Chronic; Cerebellar Cortex; Clinical Trials as Topic; Female; Hu | 1976 |
[Clinical use of piracetam in chronic alcoholism and its complications predelirium and delirium].
Topics: Alcohol Withdrawal Delirium; Alcoholism; Clinical Trials as Topic; Drug Therapy, Combination; Halope | 1976 |
[Neuropeptides in the treatment of alcoholism and alcoholic psychoses].
Topics: Administration, Intranasal; Adrenocorticotropic Hormone; Adult; Alcohol Amnestic Disorder; Alcoholis | 1986 |
Treatment of alcohol organic mental disorder with piracetam.
Topics: Adult; Age Factors; Alcoholism; Clinical Trials as Topic; Cognition; Double-Blind Method; Female; Hu | 1987 |
Piracetam in alcoholic organic mental disorder: a placebo controlled study comparing two dosages.
Topics: Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1986 |
19 other studies available for piracetam and Alcohol Abuse
| Article | Year |
|---|---|
Levetiracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients.
Topics: Adult; Alcoholism; Anticonvulsants; Benzodiazepines; Cohort Studies; Drug Therapy, Combination; Fema | 2014 |
Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Ambulatory Care; Anticonvulsants; Female; Hum | 2010 |
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.
Topics: Alcohol Drinking; Alcoholism; Animals; Anticonvulsants; beta-Endorphin; Disease Models, Animal; Dose | 2011 |
A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series.
Topics: Adult; Aged; Alcoholism; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Levetirace | 2011 |
Levetiracetam in the treatment of alcohol dependence: toward the end of the story?
Topics: Alcoholism; Anticonvulsants; Baclofen; Double-Blind Method; GABA Agonists; Humans; Levetiracetam; Pi | 2012 |
Auto-antibody-negative limbic-like encephalitis as the first manifestation of Neurosyphilis.
Topics: Aged; Alcoholism; Anticonvulsants; Autoantibodies; Cognition Disorders; Epilepsy, Generalized; Human | 2013 |
Effect of Citrocard on functional activity of cardiomyocyte mitochondria during chronic alcohol intoxication.
Topics: Alcoholism; Animals; GABA Agents; gamma-Aminobutyric Acid; Male; Mitochondria, Heart; Myocytes, Card | 2007 |
[Correction of cardiotoxic effect of chronic alcoholic intoxication by GABA-ergic compounds].
Topics: Alcoholism; Animals; Disease Models, Animal; Drug Therapy, Combination; GABA Agents; gamma-Aminobuty | 2007 |
[Alcohol withdrawal].
Topics: Alcoholism; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chlormethiazole; Humans; Par | 1982 |
[The effect of nootropil on the cerebral cortex ultrastructure in rats subjected to chronic alcoholic intoxication].
Topics: Alcoholism; Animals; Cerebral Cortex; Humans; Microscopy, Electron; Neurons; Piracetam; Pyrrolidinon | 1983 |
[Possibilities of using Nootropyl in the treatment of tuberculosis].
Topics: Adult; Alcoholism; Animals; Chemical and Drug Induced Liver Injury; Female; Hepatitis, Alcoholic; Hu | 1983 |
[Use of piracetam (nootropil) on alcoholism patients under ambulatory control of withdrawal manifestations].
Topics: Adult; Alcoholism; Ambulatory Care; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pi | 1981 |
Usefulness of piracetam in intensive care.
Topics: Alcoholism; Brain Diseases; Brain Injuries; Carbon Monoxide Poisoning; Cerebrovascular Disorders; Ch | 1976 |
The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: a quantitative study.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Animals; Cerebellum; Cytoplasmic Granules; Hippocampus; Lip | 1991 |
[Evaluation of accelerated development of stable alcoholic motivation in rats for studying potential alcohol deterrents].
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Carbazoles; Ethanol; Male; Motivation; Pi | 1990 |
[Changes in the circadian rhythm of urinary cyclic adenosine monophosphate during the alcoholic withdrawal syndrome and related neurobiological correlations].
Topics: Adult; Alcoholism; Circadian Rhythm; Clonidine; Cyclic AMP; Female; Humans; Piracetam; Sleep Initiat | 1985 |
[Use of preparations from the nootropic group for treating memory disorders in chronic alcoholism].
Topics: Adult; Alcoholism; Drug Evaluation; Etimizol; Humans; Imidazoles; Memory; Memory Disorders; Piraceta | 1988 |
[Neurophysiological analysis of the correction by nootropic substances of disorders in the bioelectric activity of the brain in animals during chronic administration of ethanol].
Topics: Alcoholism; Animals; Brain; Electroencephalography; Hippocampus; Male; Picolines; Piracetam; Pyrroli | 1988 |
Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility.
Topics: Alcohol Drinking; Alcoholism; Animals; Dihydroergotoxine; Ethanol; Male; Meglumine; Mice; Mice, Inbr | 1985 |